ArticleMolecular medicine (Cambridge, Mass.)2022
Resveratrol ameliorates liver fibrosis induced by nonpathogenic Staphylococcus in BALB/c mice through inhibiting its growth.
Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The efficacy of resveratrol in the treatment of liver fibrosis: a systematic review and meta-analysis of preclinical studies.Frontiers in nutrition · 2025Pooled it
- Review
- Ultra-processed foods sourced 7-ketositosterol aggravates colitis through gut dysbiosis induced-PDLIM3 activation.Gut microbes · 2025Article
- Resveratrol ameliorates CClMolecular biology reports · 2025Article
- Bone mesenchymal stem cells attenuate hepatic stellate cell activation and liver fibrosis through REDD1/autophagy pathway.Stem cells translational medicine · 2025Article
- Resveratrol Alleviates Arsenic Exposure-Induced Liver Fibrosis in Rats by Inhibiting Hepatocyte Senescence.Biological trace element research · 2025Article
- Quinazolinone Derivative MR2938 Protects DSS-Induced Barrier Dysfunction in Mice Through Regulating Gut Microbiota.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Novel probioticFrontiers in microbiology · 2025Article
- Ginsenoside Reshapes Intestinal Microecology to Alleviate Microgravity Stress.Drug design, development and therapy · 2025Article
- Electroacupuncture Improves Myocardial Fibrosis in Association With Intestinal Flora and Metabolic Modulation in Mice.Cardiology research and practice · 2025Article
- Lung-gut axis, intestinal microbiota, and pulmonary fibrosis: mechanisms and therapeutic potential.Frontiers in microbiology · 2025Review
- Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota.International journal of molecular sciences · 2024Review
- Article
- Resveratrol as a Promising Nutraceutical: Implications in Gut Microbiota Modulation, Inflammatory Disorders, and Colorectal Cancer.International journal of molecular sciences · 2024Review
- Potential mechanisms of traditional Chinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota.Frontiers in microbiology · 2024Review
- Identification of microRNAs implicated in modulating resveratrol-induced apoptosis in porcine granulosa cells.Frontiers in cell and developmental biology · 2023Article
- Polysaccharide from aerial part ofFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe altered gut microbiota is implicated in the pathogenesis of liver fibrosis. Resveratrol is a candidate for the treatment of liver fibrosis, which could ameliorate the dysregulation of gut microbiota in mice. This study aimed to clarify the role and mechanism of resveratrol in gut microbiota during liver fibrosis.
methodsA mouse model of liver fibrosis induced by CCl
resultsResveratrol relieved CCl
conclusionResveratrol ameliorated liver fibrosis by restraining the growth of Staphylococcus_xylosus and Staphylococcus_lentus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.